Miltefosine in children with visceral leishmaniasis

Indian Pediatrics

Volumn 43, Issue 12, 2006, Pages 1076-1080

  Singh, Utpal Kant ^a,c   Prasad, Rajniti ^b   Kumar, Ranjeet ^b   Jaiswal, Bir Prasad ^b  

^a Nalanda Medical College   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c NONE   (India)

Author keywords

Miltefosine; SAG (Sodium antimony gluconate); Visceral leishmaniasis (VL)

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ANTIEMETIC AGENT; ANTIMONY GLUCONATE; ASPARTATE AMINOTRANSFERASE; CREATININE; MILTEFOSINE;

ADOLESCENT; ANOREXIA; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FEVER; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCYTOPENIA; PARASITOLOGY; PORTAL HYPERTENSION; RASH; RELAPSE; SIDE EFFECT; SPLENOMEGALY; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; VISCERAL LEISHMANIASIS; VOMITING;

ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL; MALE; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES;

EID: 33845893040     PISSN: 00196061     EISSN: 00196061     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Desjeux P. Leishmaniasis: public health aspects and control. Clin Dermatol 1996; 14: 417-423.
2. Croft SL, Neal RA, Pendergast W, Chan JH. The activity of alkylphosphocholines and related derivatives against Leishmania donovani. Biochemical Parasitol 1987; 42: 2633-2636.
3. Kuhlencord A, Maniera T, Eibl H, Unger C. Hexadecyl phosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrobial agents Chemotherapy 1992; 36: 1630-1634.
4. Jendrossek V, Handrick R. Membrane targeted anticancer drugs: potent inducer of apoptosis and putative radiosensitisers. Curr Med Chem Anti-Canc Agents 2003; 3: 343-353.
5. Cancer therapy Evaluation Program. Common toxicity criteria.Rockville.Md: National cancer Institute. 2002(accessed April 4,2006,at://ctep.cancer.gov/ reporting/index.html.)
6. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-1746.
7. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine in children with mild to moderate Indian visceral leishmanisis. Pediatr Infect Dis J 2003; 22: 434-438.
8. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6: 928-934.
9. Jha SN, Singh NKP, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991; 39: 314-316.
10. Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony resistant kala-azar patients: a randomized controlled study .Am J Trop Med Hyg 1991; 45: 435-441.